Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IONS |
---|---|---|
09:32 ET | 38878 | 41.8 |
09:34 ET | 800 | 41.78 |
09:36 ET | 447 | 42.13 |
09:41 ET | 300 | 42.27 |
09:45 ET | 800 | 42.185 |
09:48 ET | 100 | 42.185 |
09:50 ET | 200 | 42.185 |
09:52 ET | 1169 | 42.155 |
09:54 ET | 713 | 42.1813 |
09:56 ET | 1827 | 42.135 |
09:57 ET | 300 | 42.11 |
09:59 ET | 900 | 42.195 |
10:01 ET | 508 | 42.25 |
10:03 ET | 1287 | 42.24 |
10:06 ET | 200 | 42.29 |
10:10 ET | 1300 | 42.21 |
10:12 ET | 200 | 42.15 |
10:14 ET | 1800 | 42.12 |
10:15 ET | 689 | 42 |
10:17 ET | 1257 | 42.09 |
10:19 ET | 1100 | 42.12 |
10:21 ET | 600 | 42.11 |
10:26 ET | 806 | 42.15 |
10:28 ET | 674 | 42.17 |
10:30 ET | 415 | 42.23 |
10:32 ET | 340 | 42.234 |
10:33 ET | 800 | 42.185 |
10:35 ET | 734 | 42.18 |
10:37 ET | 400 | 42.17 |
10:39 ET | 684 | 42.145 |
10:42 ET | 200 | 42.06 |
10:44 ET | 728 | 42.1 |
10:46 ET | 1078 | 42.11 |
10:48 ET | 200 | 42.085 |
10:50 ET | 1418 | 42.085 |
10:51 ET | 600 | 42.08 |
10:53 ET | 100 | 42.055 |
10:55 ET | 200 | 42 |
10:57 ET | 800 | 41.97 |
11:00 ET | 400 | 41.99 |
11:02 ET | 1045 | 41.98 |
11:04 ET | 1780 | 42.02 |
11:06 ET | 1059 | 42.02 |
11:08 ET | 548 | 42.04 |
11:09 ET | 325 | 42.14 |
11:11 ET | 300 | 42.2 |
11:13 ET | 100 | 42.23 |
11:15 ET | 956 | 42.17 |
11:18 ET | 854 | 42.175 |
11:20 ET | 1062 | 42.15 |
11:22 ET | 621 | 42.17 |
11:24 ET | 411 | 42.26 |
11:26 ET | 516 | 42.205 |
11:27 ET | 656 | 42.165 |
11:29 ET | 700 | 42.205 |
11:31 ET | 300 | 42.19 |
11:33 ET | 400 | 42.16 |
11:36 ET | 1100 | 42.08 |
11:38 ET | 875 | 42.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ionis Pharmaceuticals Inc | 6.1B | -16.5x | --- |
Halozyme Therapeutics Inc | 4.9B | 18.5x | --- |
Apellis Pharmaceuticals Inc | 6.0B | -10.8x | --- |
Intra-Cellular Therapies Inc | 7.6B | -50.3x | --- |
Blueprint Medicines Corp | 5.7B | -11.2x | --- |
ACADIA Pharmaceuticals Inc | 2.8B | -45.7x | --- |
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1B |
---|---|
Revenue (TTM) | $787.6M |
Shares Outstanding | 145.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.41 |
EPS | $-2.56 |
Book Value | $2.68 |
P/E Ratio | -16.5x |
Price/Sales (TTM) | 7.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.